司美格鲁肽辅助治疗2型糖尿病合并肥胖及原发性高血压的效果分析

Analysis of the effects of simegallutide in obese T2DM patients with essential hypertension

目的:探讨司美格鲁肽辅助治疗2型糖尿病(T2DM)合并肥胖及原发性高血压(HT)的效果。方法:选择陆军第七十三集团军医院2021年9月—2022年9月收治的T2DM伴肥胖及HT患者90例,按照随机数表法分为对照组(n=45)和观察组(n=45)。对照组给予常规治疗方案控制血糖,观察组在对照组基础上给予司美格鲁肽治疗。观察两组血糖、胰岛细胞功能、血压和体质量指数(BMI)的变化及不良反应发生情况。结果:治疗后,两组空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbAlC)、甘油三酯(TG)、血清胆固醇(TC)水平和舒张压(DBP)、收缩压(SBP)及体质量指数(BMI)均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组胰岛素抵抗指数(HOMA-IR)低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组胰岛β细胞功能指数(HOMA-β)水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:司美格鲁肽辅助治疗可以有效控制T2DM合并肥胖及HT患者的血糖、血压和BMI,改善胰岛细胞功能,且不会增加不良反应。

Objective:To study the effect of simegallutide in patients with type 2 diabetes mellitus(T2DM)with obesity and essential hypertension.Methods:All 90 patients with T2DM,obesity,and primary hypertension from the 73rd group military hospital of the army from September 2021 to September 2022 were selected as the study subjects and randomly divided into a control group(n=45)and an observation group(n=45)according to the random number table method.The control group was treated with routine treatment to control blood sugar,and the observation group was treated with simeglutide on the basis of the control group.The changes of blood glucose,islet cell function,blood pressure,BMI and adverse reactions were observed.Results:After treatment,the levels of fasting plasma glucose(FPG),2 hour postprandial plasma glucose(2 h PG),Glycated hemoglobin acid(HbAlC),triglyceride acid(TG),serum cholesterol(TC),diastolic blood pressure(DBP),systolic blood pressure(SBP)and body mass index(BMI)in both groups were lower than those before treatment,and the observation group was lower than the control group,the difference was statistically significant(P<0.05).After treatment,the higher insulin resistance index(HOMA-IR)in the two groups was lower than that before treatment,and the HOMA-IR in the observation group was lower than that in the control group(P<0.05).After treatment,the level of isletβ-cell function index(HOMA-β)in the two groups was higher than that before treatment,and the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).Conclusion:The adjuvant treatment of T2DM patients with obesity and HT can effectively control blood glucose,blood pressure and BMI,and improve islet cell function without increasing the occurrence of adverse effects.